SELLAS Life Sciences Group (SLS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
20 Nov, 2026GPS clinical results and development
REGAL met its primary OS endpoint in transplant-ineligible AML in CR2 or later: 41% lower risk of death; median OS 24.0 vs 14.7 months, HR 0.59, p=0.035.
The randomized global Phase 3 trial enrolled 126 patients; GPS was generally well tolerated, with mostly Grade 1/2 treatment-related AEs and no new safety signals.
FDA discussions and preparations for an expedited BLA are planned; GPS also has potential label expansion after CR1 and post-transplant.
GPS is an engineered, multivalent WT1-targeting immunotherapy; WT1 is expressed in ~97% of AML, with potential application across 20+ hematologic and solid cancers.
SLS009 clinical progress
Completed Phase 2 study met all primary endpoints; at the optimal 30 mg BIW dose, ORR was 40% and median OS was 8.8 months in r/r AML after venetoclax-based therapy.
In adverse-risk subsets, monocytic AML had 54% ORR and 5.8-month median OS; TP53-mutated AML had 57% ORR and 8.8-month median OS.
No dose-limiting toxicities or treatment-related high-grade toxicities were observed; hematologic toxicity was consistent with aza/ven alone.
The 80-patient frontline AML Phase 2 trial has enrolled 40; cohorts target patients predicted not to benefit from aza/ven or with confirmed early nonresponse, with preliminary data expected Q4 2026.
SLS009 mechanism and research
SLS009 is a selective CDK9 inhibitor designed to suppress CDK9 by ~99.7%; CDK9 inhibition may reduce MCL-1 and c-MYC, promoting apoptosis and cell-cycle arrest.
In a daraxonrasib-resistant pancreatic cancer model, SLS009 induced 17.9% apoptosis and 14.5% necrosis, versus 2.8% and 2.7% with daraxonrasib.
The NIH-funded PIVOT program evaluates SLS009 in pediatric tumors; in 27 patient-derived ALL models, median survival approximately tripled versus vehicle and 25/27 models showed delayed progression.
Latest events from SELLAS Life Sciences Group
- GPS advances in Phase 3 AML as SLS009 delivers promising Phase 2 results.SLS
Corporate presentation - REGAL: GPS cut death risk 41% and extended median OS to 24.0 months.SLS
Study result - REGAL topline results are expected in November as SLS009 advances, with $134.7 million in cash.SLS
Q3 2026 - Net loss rose to $18.0M in H1 2026; cash reached $138.3M as clinical programs advanced.SLS
Q2 2026 - All proposals passed amid strong financial growth and clinical progress toward pivotal milestones.SLS
AGM 2026 - Pivotal AML trial data for GPS and phase II results for SLS009 are expected to drive major milestones.SLS
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials.SLS
A.G.P.'s Annual Virtual Healthcare Conference - Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts.SLS
Stifel 2026 Targeted Oncology Virtual Forum - GPS and SLS009 advance as late-stage, first-in-class AML therapies with pivotal data imminent.SLS
R&D Day 2025